All
Non Transplant Treatments for MDS & Secondary AML
July 24th 2018Dr. Toyosi Odenike, University of Chicago and Dr. Eric Padron, H. Lee Moffitt Cancer Center, discuss the highlights of their session on Non-Transplant Treatments for Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (AML) at the 2018 AAMDSIF International Bone Marrow Failure Disease Scientific Symposium, March 2018.
PARP Inhibitors May Bring New Hope to Patients With Small Cell Lung Cancer
July 17th 2018Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).
Genetic Mutation Can Predict Acute Myeloid Leukemia Risk a Decade Before Diagnosis
July 17th 2018While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.
Cramps or Cancer: Elevated Menstrual Pain May be Associated with Ovarian Cancer Risk
July 17th 2018Researchers reviewed the cases of more than 20,000 women – some who went on to develop ovarian cancer, and some who didn’t – and found that there was a small, but statistically significant increase in ovarian cancer incidence in women who reported having severe menstrual pain.
Pre-Surgical Bladder Cancer Treatment: What's Next
July 16th 2018Many questions still remain in the treatment of localized bladder cancer, like which patients are best suited to receive neoadjuvant (pre-surgery) chemotherapy – a procedure that could be beneficial to many, but comes with increased toxicity.